Amarantus has been awarded composition of matter patents in the United States and Europe covering MANF. The Company has also filed a number of continuations and pending patent applications for MANF. In 2012, Amarantus won a challenge to its European composition of matter patents against a private European-based biotechnology company. The Company is planning to reprioritize its therapeutic pipeline to identify the most viable near-term market opportunity based on studies currently ongoing with MANF in various orphan indications through its research grant from the Center of Excellence of Apoptosis Research in Massachusetts awarded in late 2012. The first orphan indication identified for MANF is in Retinitis Pigmentosa, an ophthalmological condition with no current effective therapy that results in rod and cone degeneration in the eye affecting roughly 100,000 people in the US, 100,000 people in Europe and 50,000 people in Japan, representing a potential market estimated at $10 billion.
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro TestŪ") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook&u=http%3A%2F%2Fwww.facebook.com%2Famarantusbio">Facebook, LinkedIn, Twitter&u=https%3A%2F%2Ftwitter.com%2FAmarantusBio">Twitter and Google+.
CONTACT: Investor/Media Contacts
Russell Miller, Director of Investor Relations
408.737.2734 x 109
Source: Amarantus BioScience Holdings, Inc.